GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

GSK is a Brentford, England-based pharmaceutical company. It holds a majority stake in ViiV, a London-based developer of treatments for HIV and AIDS. ViiV is currently advancing its Cabenuva prescription treatment, a long-acting injectable which combines cabotegravir and rilpivirine for the treatment of patients with HIV-1.

GSK said that phase III trials of Cabenuva had demonstrated ‘superior efficacy in maintaining viral load suppression compared to daily oral therapy’ in patients with a history of antiretroviral treatment challenges.

Kimberley Smith, head of research and development at ViiV, said: ‘The interim data indicating the superiority of long-acting therapy compared to daily oral therapy in individuals who have difficulty taking pills for HIV every day is a remarkable outcome.

‘Optimising therapy for all people living with HIV, including those with adherence challenges, is critical to the effort to end the HIV epidemic.’

Trials of Cabenuva are ongoing across 31 sites in the US, and are funded by the National Institute of Allergy and Infectious Diseases.

Shares in GSK were down 1.1% at 1,659.80 pence each in London on Wednesday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.